Press "Enter" to skip to content

Hikma core operating profit jumps on higher sales of injectable drugs

The Jordan-based drugmaker said its core operating profit rose to $460 million for the year ended Dec. 31 from $386 million a year earlier.

Original source: https://health.economictimes.indiatimes.com/news/pharma/hikma-core-operating-profit-jumps-on-higher-sales-of-injectable-drugs/68389282?utm_source=RSS&utm_medium=ETRSS

Also Read:   AbbVie's Skyrizi drug to treat psoriasis wins U.S. approval